MedTrace Logo

Lifetech LAmbre™ Left Atrial Appendage (LAA) Closure System Post-Market Clinical Follow-up Study

NCT03666780 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-07-04

No results posted yet for this study

Summary

Multi-center, single-arm, prospective, post-market study of LAmbre™ LAA Closure System. To evaluate the immediate and long-term procedural success of Lifetech LAmbre™ occluders in patients.

Conditions

Interventions

DEVICE

LAmbre Occluder

All patients are implanted with Lifetech LAmbre occluder device.

Sponsors & Collaborators

  • IQVIA Biotech

    collaborator INDUSTRY

  • Lifetech Scientific (Shenzhen) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Horst Sievert, Prof · CVC CardioVasculäres Centrum Frankfurt

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-16
Primary Completion
2021-11-29
Completion
2024-09-30

Countries

  • China
  • Denmark
  • Germany
  • Ireland
  • Italy
  • Poland
  • Spain
  • Sweden
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03666780 on ClinicalTrials.gov